Long title
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
Date receipt dossier
EudraCT number
2024-511188-26
Company / Sponsor
Kite Pharma
Phase
III
Treated organism
Humans
Indication category
Cancer therapy
Disease
multiple myeloma
Therapeutic approach
Immunotherapy
Genetic modification
ddBCMA CAR
Method of transfer of nucleic acid of interest
Lentiviral vector
Administered biological material
Autologous T cells transduced with lentiviral vectors expressing D-domain BCMA-CAR
Route of administration
Intravenous
Locations in Belgium
UZ Leuven, Cliniques Universitaires Saint-Luc, UZ Antwerpen, U Gent
Nr of subjects
450
Foreseen duration
2024-2041
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
CART-ddBCMA-cel